Roche Holding Ltd · SIX:RO

Roche — ASCO Gastrointestinal Cancers Symposium 2024

10 slides from Roche's conference presentation, 2024

  1. Slide 1: Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer (IMbrave151)

    Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Results From a Randomized Proof-of-Concept Phase II Trial (IMbrave151) Anthony B. El-Khoueiry,1 Zhenggang Ren,2 Hong Jae Chon,3 Joon Oh Park,4 Jin Won Kim,5 Tiziana Pressiani,6 Daneng Li,7 Lyudmila Zhukova,8

  2. Slide 2: IMbrave151 study design (NCT04677504)

    IMbrave151 study design (NCT04677504)1 Cycles 1-8 Cycle 9 and beyond (21-day cycles) (21-day cycles) Atezolizumab (1200 mg IV q3w) Advanced BTC Bevacizumab (15 mg/kg IV q3w) Treat until (n=162) • Cisplatin (25 mg/m2 IV on Days 1 and 8) disease • Histologically confirmed iCCA, eCCA or GBC progression

  3. Slide 3: Baseline characteristics

    Baseline characteristics Atezo + Bev + CisGem Atezo + PBO + CisGem (n=79) (n=83) Median age (range), years 61.0 (36-79) 65.0 (37-79) Age <65 years, n (%) 51 (65) 38 (46) Male, n (%) 49 (62) 38 (46) Race, n (%) White 41 (52) 46 (55) Asian 37 (47) 35 (42) Region, n (%)a Asia 34 (43) 35 (42) Rest of wo

  4. Slide 4: Updated PFS and OS

    Updated PFS and OS Atezo + Bev + Atezo + PBO + Atezo + Bev + Atezo + PBO + Primary endpoint: PFS CisGem CisGem Secondary endpoint: OS CisGem CisGem (n=79)a (n=83) (n=79)a (n=83) No. of events (%) 63 (80) 73 (88) No. of events (%) 47 (59) 48 (58) Median PFS (95% CI), mo 8.3 (6.8, 10.6) 7.9 (6.2, 8.5)

  5. Slide 5: Secondary endpoints: ORR and DOR

    Secondary endpoints: ORR and DOR Atezo + Bev + Atezo + PBO + Atezo + Bev + Atezo + PBO + CisGem CisGem Confirmed response, n (%) CisGem CisGem (n=21) (n=22) (n=79) (n=83) No. of events (%) 14 (67) 19 (86) Median DOR, mo (95% CI) 10.3 (6.7, 16.7) 6.2 (4.3, 6.7) ORRa 21 (27) 22 (27) 95% CI 17.3, 37.7

  6. Slide 6: Safety summary

    Safety summary CIT + chemotherapy phase CIT-only phase Overall period (n=159) (n=107) (n=159) Atezo + Bev + Atezo + PBO + Atezo + Bev + Atezo + PBO + CisGem CisGem Atezo + Bev Atezo + PBO CisGem CisGem (n=78) (n=81) (n=54) (n=53) (n=78) (n=81) Atezo: 7.6; Atezo: 6.7; Treatment duration, median, mo N

  7. Slide 7: Exploratory endpoint: Gene expression and signatures

    Exploratory endpoint: Gene expression and signatures • High VEGFA gene expression and enrichment of hepatocytes may be associated with longer PFS and OS in patients treated with Atezo + Bev + CisGem • High PI3K/AKT/MTOR pathway activation may be associated with less clinical benefit in the Atezo + B

  8. Slide 8: Exploratory endpoint: PFS and OS by VEGFA status

    Exploratory endpoint: PFS and OS by VEGFA status VEGFA high VEGFA low PFS (%) PFS (%) HR: 0.427 (95% CI: 0.22, 0.829) No. at risk Time (mo) No. at risk Time (mo) VEGFA high VEGFA low OS (%) OS (%) HR: 0.655 (95% CI: 0.311, 1.38) No. at risk Time (mo) No. at risk Time (mo) Median follow-up duration:

  9. Slide 9: Exploratory endpoint: OS by PI3K/AKT status

    Exploratory endpoint: OS by PI3K/AKT status PI3K/AKT mutation PI3K/AKT wild type OS (%) OS (%) HR: 3.95 (95% CI: 1.3, 12) No. at risk Time (mo) No. at risk Time (mo) Atezo + Bev + CisGem Atezo + PBO + CisGem OS (%) OS (%) HR: 3.29 (95% CI: 1.41, 7.68) No. at risk Time (mo) No. at risk Time (mo) Medi

  10. Slide 10: Conclusions

    Conclusions • At final analysis, IMbrave151 showed improvement in the primary endpoint of PFS Acknowledgments (HR, 0.67; 95% CI: 0.46, 0.95) in intention-to-treat patients with the addition of • The patients and their families bevacizumab to atezolizumab + chemotherapy • The investigators and clinic

Roche Holding — ASCO Gastrointestinal Cancers Symposium 2024 on 6ix